Cancer stem cell targeting: Are we there yet?

Several decades after the first notion that cancer cells are heterogeneous, not only histologically but also at the level of tumorigenicity, the existence of a tumor initiation population (so-called cancer stem cells) is now widely accepted. Here, we review the historical background leading up to th...

Full description

Saved in:
Bibliographic Details
Published in:Archives of pharmacal research 2015, 38(3), , pp.414-422
Main Authors: Jung, Yuchae, Kim, Woo-Young
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Drug Design
Drug Resistance, Neoplasm
Humans
Medicine
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - pathology
Neoplastic Stem Cells - metabolism
Pharmacology/Toxicology
Pharmacy
Review
Signal Transduction - drug effects
약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several decades after the first notion that cancer cells are heterogeneous, not only histologically but also at the level of tumorigenicity, the existence of a tumor initiation population (so-called cancer stem cells) is now widely accepted. Here, we review the historical background leading up to the identification of this special cancer cell population and its role in the resistance of tumors to conventional therapies. In addition, we briefly review the clinical targeting strategy of the specific signaling network for cancer stem cells. Current clinical trials with newly developed drugs or older drugs for other uses are summarized to provide an understanding of the current status of strategies to target cancer stem cells.
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-015-0570-2